VIVUS Inc (VVUS.O)

VVUS.O on Nasdaq

2.69USD
26 Jan 2015
Change (% chg)

$-0.05 (-1.82%)
Prev Close
$2.58
Open
$2.72
Day's High
$2.72
Day's Low
$2.64
Volume
1,423,320
Avg. Vol
2,183,113
52-wk High
$8.36
52-wk Low
$2.56

VVUS.O

Chart for VVUS.O

About

VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $284.08
Shares Outstanding(Mil.): 103.68
Dividend: --
Yield (%): --

Financials

  VVUS.O Industry Sector
P/E (TTM): -- 40.21 40.82
EPS (TTM): -0.72 -- --
ROI: -21.32 19.07 18.35
ROE: -57.25 19.85 19.25
Search Stocks

CORRECTED-UPDATE 1-Vivus' Stendra gets FDA approval for use 15 minutes before sex

(Corrects headline and first paragraph to make clear that Stendra was already approved for use 30 minutes before sex, and has now been approved for use as little as 15 minutes before sex)

18 Sep 2014

Vivus' Stendra gets FDA approval for use 15 minutes before sex

- The erectile dysfunction drug Stendra, currently approved by the U.S. Food and Drug Administration for use 30 minutes before sex, has now been approved for use as little as 15 minutes before sex, the drug's developers said on Thursday.

18 Sep 2014

CORRECTED-Vivus' Stendra gets FDA approval for use 15 minutes before sex

(Corrects headline and first paragraph to make clear that Stendra was already approved for use 30 minutes before sex, and has now been approved for use as little as 15 minutes before sex)

18 Sep 2014

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

11 Sep 2014

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

10 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks